



Fig. sup. 1. Plasma-derived exosomes isolation and characterization



A. Representative TEM image of isolated particles from metastatic ER+ breast cancer plasma sample. Scale bar = 100 nm. **B.** Expression of exosome-positive (TSG101 and CD81) and exosome-negative (calnexin) protein markers determined by Western blot in two different ER+ breast cancer cell lines (T47D and MCF7) and exosomes isolated from plasma samples. **C.** Nanoparticle tracking analysis (NTA) of exosomes isolated from plasma samples by ultracentrifugation. Data represent the size distribution profile of three different isolated samples. Data for each individual sample derive from three different videos and analyses.

Fig S2. miR-155-5p is associated with inflammation and treatment response



A. Time-dependent ROC curves showing the discriminatory performance of the miR-155-5p/miR-143-3p expression ratio for PFS at 12, 18, and 24 months after treatment initiation. The area under the curve (AUC) increased from 0.64 (95% CI: 0.49–0.79) at 12 months to 0.69 (95% CI: 0.56–0.82) at 18 months and remained stable at 24 months (AUC 0.69, 95% CI: 0.57–0.80), indicating improved predictive accuracy over time.